[
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors despite losses on the day",
    "summary": "Biogen Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=40de838fc8957ce5b93c73ec1889f57dba017c36726f838ed141edc885d92ef1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732295220,
      "headline": "Biogen Inc. stock outperforms competitors despite losses on the day",
      "id": 131611818,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=40de838fc8957ce5b93c73ec1889f57dba017c36726f838ed141edc885d92ef1"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock",
    "summary": "We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial […]",
    "url": "https://finnhub.io/api/news?id=3523d3f170465ffa6caf46a6bcc1ea6a9fa88fe75a55de79aaf042224e8ccbad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732279541,
      "headline": "Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock",
      "id": 131563445,
      "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial […]",
      "url": "https://finnhub.io/api/news?id=3523d3f170465ffa6caf46a6bcc1ea6a9fa88fe75a55de79aaf042224e8ccbad"
    }
  },
  {
    "ts": null,
    "headline": "Biogen price target lowered to $207 from $251 at Mizuho",
    "summary": "Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. Biogen’s Q3 contained no major surprises, but Mizuho cut the price target on a slow Leqembi launch, the analyst tells investors in a research note. The firm continues to see the Biogen story as a longer term positive, largely on how and when the Leqembi launch could accelerate. Published first on Th",
    "url": "https://finnhub.io/api/news?id=6a39563f4916dcb5496900f4c1b41fab16d90d8b1d3be395debe5f4be80b18d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732275912,
      "headline": "Biogen price target lowered to $207 from $251 at Mizuho",
      "id": 131563448,
      "image": "",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. Biogen’s Q3 contained no major surprises, but Mizuho cut the price target on a slow Leqembi launch, the analyst tells investors in a research note. The firm continues to see the Biogen story as a longer term positive, largely on how and when the Leqembi launch could accelerate. Published first on Th",
      "url": "https://finnhub.io/api/news?id=6a39563f4916dcb5496900f4c1b41fab16d90d8b1d3be395debe5f4be80b18d0"
    }
  }
]